BioVentus (BVS) Q2 FY26 earnings call

BioVentus delivered solid Q2 FY26 results, driven by strong performance in Pain Treatments and disciplined cost management, leading to increased earnings and significant debt reduction. The company also announced a strategic review process initiated by its Board of Directors to evaluate options, including a potential sale, to maximize shareholder value. Despite some segment-specific headwinds, management reaffirmed full-year guidance, expressing confidence in its growth drivers and operational execution.